% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{VogelClaussen:181016,
      author       = {J. Vogel-Claussen and F. Lasch and B.-A. Bollmann and K.
                      May and A. Kuhlmann and G. Schmid-Bindert and R. Kaaks$^*$
                      and J. Barkhausen and S. Bohnet and M. Reck},
      title        = {{D}esign and {R}ationale of the {HANSE} {S}tudy: {A}
                      {H}olistic {G}erman {L}ung {C}ancer {S}creening {T}rial
                      {U}sing {L}ow-{D}ose {C}omputed {T}omography [{D}esign und
                      {R}ationale der {HANSE}-{S}tudie: {E}ine ganzheitliche
                      deutsche {L}ungenkrebs-{F}rüherkennungs-{S}tudie unter
                      {V}erwendung von {N}iedrigdosis-{C}omputertomografie].},
      journal      = {RöFo},
      volume       = {194},
      number       = {12},
      issn         = {0015-8151},
      address      = {Stuttgart [u.a.]},
      publisher    = {Thieme},
      reportid     = {DKFZ-2022-01724},
      pages        = {1333-1345},
      year         = {2022},
      note         = {2022 Dec;194(12):1333-1345},
      abstract     = {Despite the high prevalence and mortality of lung cancer
                      and proven effectiveness of low-dose computed tomography
                      (LDCT) to reduce mortality, Germany still lacks a national
                      screening program. The German Institute for Quality and
                      Efficiency in Health Care (IQWiG) and the Federal Office for
                      Radiation Protection (BfS) both published positive
                      scientific evaluations recommending a quality-controlled
                      national screening program. IQWiG underlined the importance
                      of a clear risk definition, integrated smoking cessation
                      programs, and quality assurance, highlighting the necessity
                      of procedural optimization. In the HANSE study, former and
                      current smokers aged 55-79 years are assessed for their lung
                      cancer risk by the NELSON and PLCOM2012 risk scores. 5000
                      high-risk participants, defined as PLCOM2012 6-year risk ≥
                      1.58 $\%$ or fulfilling NELSON risk inclusion criteria, will
                      be screened by LDCT at baseline and after 12 months. Lung
                      nodules are analyzed by a modified Lung-RADS 1.1 score of
                      the HANSE study, and values of emphysema and coronary
                      calcium are determined and randomly reported to the
                      participants. 7100 low-risk participants serve as a control.
                      All patients are followed-up for up to 10 years. The
                      sensitivity and specificity of the two risk assessments and
                      LDCT screening, effects of the randomized LDCT reporting,
                      efficiency of lung nodule management, and several other
                      factors are assessed to analyze the success and quality of
                      the holistic screening program. The HANSE study is designed
                      as a holistic lung cancer screening study in northern
                      Germany to answer pressing questions for a successful
                      implementation of an effective German lung cancer screening
                      program. · HANSE is designed to address pressing questions
                      for the implementation of lung cancer screening in Germany..
                      · HANSE compares NELSON and PLCOM2012 risk assessments for
                      optimal definition of the high-risk group. . · HANSE
                      integrates cardiac calcium and pulmonary emphysema scoring
                      in a holistic screening approach..· Vogel-Claussen J, Lasch
                      F, Bollmann B et al. Design and Rationale of the HANSE
                      Study: A Holistic German Lung Cancer Screening Trial Using
                      Low-Dose Computed Tomography. Fortschr Röntgenstr 2022;
                      DOI: 10.1055/a-1853-8291.},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35917826},
      doi          = {10.1055/a-1853-8291},
      url          = {https://inrepo02.dkfz.de/record/181016},
}